Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Home
/
update
/
details

Agilent Unveils ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit

NextEdge Admin

22 Jul 2024

2 min 14 sec

Cell therapy,gene therapy,Pharmaceutical

Agilent has unveiled its new protein analysis platform, the ProteoAnalyzer, an automated parallel capillary electrophoresis (CE) solution. This advanced system offers rapid, high-resolution analysis while minimizing sample consumption, enabling researchers to efficiently study complex protein mixtures. The platform is poised to accelerate discoveries in pharmaceuticals, biopharmaceuticals, and bioengineered food ingredients.

Carsten Thomsen, Associate Vice President of APAC Sales for the Diagnostics and Genomics Group at Agilent, expressed enthusiasm for the launch: "The ProteoAnalyzer integrates cutting-edge biomolecular technologies, enhancing translational research from compound discovery to novel applications. Building on Agilent's established CE capabilities, the ProteoAnalyzer is designed to prioritize breakthrough discoveries that improve quality of life."

Pharmaceutical and biopharmaceutical companies are increasingly adopting CE solutions to advance the development of therapeutic proteins. Agilent's ProteoAnalyzer supports this trend with user-friendly QC workflows for evaluating the size and purity of proteins, including antibodies, enzymes, and other proteins of interest.

Additionally, Agilent introduced an update to its Flow Cytometer product line at SCGT. The new NovoCyte Opteon, featuring up to five lasers and 73 detectors, is set to transform cell analysis research.

For 25 years, Agilent has supported clinical laboratories worldwide in delivering safe and effective health solutions. In the Asia Pacific region, Agilent collaborates with research institutes such as Singapore's ACTRIS and South Korea's Theragen Bio, underscoring the company's commitment to advancing medical research through innovative technology.